NanoIVD Inc. researches, develops, and commercializes blood-based tests for early cancer screening, cancer-recurrence monitoring, treatment-effectiveness monitoring, and personalized molecular cancer profiling for therapeutic selection. It owns an algorithm for cancer biomarker selection and proprietary nanowire field-effect-transistor (NW-FET) chip technology for label-free, real-time in-vitro diagnostic (IVD) testing.
Recent- Dr. Berwyn Clarke is a senior executive in the in-vitro diagnostic industry and a new member of the Board of Advisors. Continue reading
Archive -The U.S. Patent and Trademark Office (USPTO) has issued patent number 8,323,466 for NanoIVD’s nanowire biosensor technology on December 4, 2012. Continue reading